Yang et al. summarized that antibody targeting the immune checkpoint gene CD276 significantly inhibited CD276-positive tumor cells through antibody-dependent cellular cytotoxicity [59], as enoblituzumab can play a therapeutic role in melanoma. The gene discussed is CD276; the disease is melanoma.